Business Description
Mesa Laboratories Inc
NAICS : 334513
SIC : 3823
ISIN : US59064R1095
Share Class Description:
MLAB: Ordinary SharesTotal Employee Number:
717Description
Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.17 | |||||
Equity-to-Asset | 0.44 | |||||
Debt-to-Equity | 0.83 | |||||
Debt-to-EBITDA | 3.38 | |||||
Interest Coverage | 1.73 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 1.57 | |||||
Beneish M-Score | -2.85 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.1 | |||||
3-Year EBITDA Growth Rate | 5.7 | |||||
3-Year EPS without NRI Growth Rate | 92.4 | |||||
3-Year FCF Growth Rate | 17.6 | |||||
3-Year Book Growth Rate | -22.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.17 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 53.33 | |||||
9-Day RSI | 46.68 | |||||
14-Day RSI | 46.85 | |||||
3-1 Month Momentum % | 29.95 | |||||
6-1 Month Momentum % | 34.67 | |||||
12-1 Month Momentum % | 10.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.72 | |||||
Quick Ratio | 1.29 | |||||
Cash Ratio | 0.44 | |||||
Days Inventory | 107.77 | |||||
Days Sales Outstanding | 60.2 | |||||
Days Payable | 21.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.63 | |||||
Dividend Payout Ratio | 0.53 | |||||
Forward Dividend Yield % | 0.63 | |||||
5-Year Yield-on-Cost % | 0.63 | |||||
3-Year Average Share Buyback Ratio | -1 | |||||
Shareholder Yield % | 6.12 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 63.53 | |||||
Operating Margin % | 7.43 | |||||
Net Margin % | 2.69 | |||||
EBITDA Margin % | 18.46 | |||||
FCF Margin % | 15.89 | |||||
OCF Margin % | 17.19 | |||||
ROE % | 3.8 | |||||
ROA % | 1.55 | |||||
ROIC % | 2.55 | |||||
ROC (Joel Greenblatt) % | 37.57 | |||||
ROCE % | 6.74 | |||||
Years of Profitability over Past 10-Year | 7 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 81.79 | |||||
Forward PE Ratio | 66.45 | |||||
PE Ratio without NRI | 81.79 | |||||
Price-to-Owner-Earnings | 25.09 | |||||
PS Ratio | 2.2 | |||||
PB Ratio | 2.91 | |||||
Price-to-Free-Cash-Flow | 13.84 | |||||
Price-to-Operating-Cash-Flow | 12.77 | |||||
EV-to-EBIT | 29.53 | |||||
EV-to-EBITDA | 14.58 | |||||
EV-to-Forward-EBITDA | 28.58 | |||||
EV-to-Revenue | 2.69 | |||||
EV-to-Forward-Revenue | 7.14 | |||||
EV-to-FCF | 16.94 | |||||
Price-to-GF-Value | 0.85 | |||||
Price-to-Projected-FCF | 0.98 | |||||
Price-to-Median-PS-Value | 0.39 | |||||
Earnings Yield (Greenblatt) % | 3.39 | |||||
FCF Yield % | 7.3 | |||||
Forward Rate of Return (Yacktman) % | 17.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MLAB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mesa Laboratories Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 249.13 | ||
| EPS (TTM) ($) | 1.2 | ||
| Beta | 0.66 | ||
| 3-Year Sharpe Ratio | -0.06 | ||
| 3-Year Sortino Ratio | -0.09 | ||
| Volatility % | 40.17 | ||
| 14-Day RSI | 46.85 | ||
| 14-Day ATR ($) | 6.019448 | ||
| 20-Day SMA ($) | 102.181 | ||
| 12-1 Month Momentum % | 10.87 | ||
| 52-Week Range ($) | 55.45 - 113.99 | ||
| Shares Outstanding (Mil) | 5.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mesa Laboratories Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mesa Laboratories Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2026-11-06 | In 133 days | ||
| General meeting for 2026 | 2026-08-21 14:00 | In 57 days | ||
| First quarter earnings results for 2027 | 2026-08-05 | In 40 days | ||
| Annual report for 2026 | 2026-06-03 | 106.66 (+2.15%) | ||
| USD 0.160000 Cash Dividend | 2026-05-29 | 103.10 (+13.55%) | ||
| Fourth quarter earnings results for 2026 | 2026-05-27 06:00 | 106.17 (-2.35%) | ||
| USD 0.160000 Cash Dividend | 2026-02-27 | 95.56 (-0.03%) | ||
| Third quarter earnings results for 2026 | 2026-02-03 08:00 | 80.50 (+2.18%) | ||
| 44th Annual J.P. Morgan Healthcare Conference | 2026-01-14 16:30 | 84.36 (+0.43%) | ||
| USD 0.160000 Cash Dividend | 2025-11-28 | 80.51 (-1.09%) |
Show
Entries
Mesa Laboratories Inc Frequently Asked Questions
What is Mesa Laboratories Inc(MLAB)'s stock price today?
The current price of MLAB is $98.18. The 52 week high of MLAB is $113.99 and 52 week low is $55.45.
When is next earnings date of Mesa Laboratories Inc(MLAB)?
The next earnings date of Mesa Laboratories Inc(MLAB) is 2026-08-05 Est..
Does Mesa Laboratories Inc(MLAB) pay dividends? If so, how much?
The Dividend Yield %  of Mesa Laboratories Inc(MLAB) is 0.63% (As of Today), Highest Dividend Payout Ratio of Mesa Laboratories Inc(MLAB) was 3.77. The lowest was 0.15. And the median was 0.76. The  Forward Dividend Yield % of Mesa Laboratories Inc(MLAB) is 0.63%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NAS:MLAB
No articles.
Press Release
Articles on Mesa Laboratories Inc
No articles.
Headlines
See More- 1
May 27, 2026
Mesa Laboratories GAAP EPS of -$0.75, revenue of $63.72M misses by $1.48M
Seeking Alpha • 7:08am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers